Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson, Albert Garcia‐Romeu, Mary P Cosimano, et al.
Journal of Psychopharmacology (2014) Vol. 28, Iss. 11, pp. 983-992
Open Access | Times Cited: 746

Showing 1-25 of 746 citing articles:

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross, Anthony P. Bossis, Jeffrey Guss, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 12, pp. 1165-1180
Open Access | Times Cited: 1334
Psychedelics
David E. Nichols
Pharmacological Reviews (2016) Vol. 68, Iss. 2, pp. 264-355
Open Access | Times Cited: 1293
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin Carhart‐Harris, Mark Bolstridge, James Rucker, et al.
The Lancet Psychiatry (2016) Vol. 3, Iss. 7, pp. 619-627
Open Access | Times Cited: 1283
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz, Alyssa A. Forcehimes, Jessica A. Pommy, et al.
Journal of Psychopharmacology (2015) Vol. 29, Iss. 3, pp. 289-299
Closed Access | Times Cited: 968
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Robin Carhart‐Harris, Mark Bolstridge, Camilla Day, et al.
Psychopharmacology (2017) Vol. 235, Iss. 2, pp. 399-408
Open Access | Times Cited: 761
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Robin Carhart‐Harris, Suresh Muthukumaraswamy, Leor Roseman, et al.
Proceedings of the National Academy of Sciences (2016) Vol. 113, Iss. 17, pp. 4853-4858
Open Access | Times Cited: 750
Long-term follow-up of psilocybin-facilitated smoking cessation
Matthew W. Johnson, Albert Garcia‐Romeu, Roland R. Griffiths
The American Journal of Drug and Alcohol Abuse (2016) Vol. 43, Iss. 1, pp. 55-60
Open Access | Times Cited: 570
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Robin Carhart‐Harris, Guy M. Goodwin
Neuropsychopharmacology (2017) Vol. 42, Iss. 11, pp. 2105-2113
Open Access | Times Cited: 500
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Robin Carhart‐Harris, Leor Roseman, Mark Bolstridge, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 464
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Frederick S. Barrett, Matthew W. Johnson, Roland R. Griffiths
Journal of Psychopharmacology (2015) Vol. 29, Iss. 11, pp. 1182-1190
Open Access | Times Cited: 461
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin Reiff, Elon E. Richman, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2020) Vol. 177, Iss. 5, pp. 391-410
Closed Access | Times Cited: 446
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2016) Vol. 30, Iss. 12, pp. 1268-1278
Open Access | Times Cited: 426
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson, Peter S. Hendricks, Frederick S. Barrett, et al.
Pharmacology & Therapeutics (2018) Vol. 197, pp. 83-102
Closed Access | Times Cited: 420
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 10, pp. 953-953
Open Access | Times Cited: 414
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Albert Garcia‐Romeu, Roland R. Griffiths, Matthew W. Johnson
Current Drug Abuse Reviews (2015) Vol. 7, Iss. 3, pp. 157-164
Open Access | Times Cited: 411
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Franz X. Vollenweider, Katrin H. Preller
Nature reviews. Neuroscience (2020) Vol. 21, Iss. 11, pp. 611-624
Closed Access | Times Cited: 406
Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)
Matthew M. Nour, Lisa Evans, David Nutt, et al.
Frontiers in Human Neuroscience (2016) Vol. 10
Open Access | Times Cited: 376
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
M. Madsen, Patrick M. Fisher, Daniel Burmester, et al.
Neuropsychopharmacology (2019) Vol. 44, Iss. 7, pp. 1328-1334
Open Access | Times Cited: 376
The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
David B. Yaden, Roland R. Griffiths
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 568-572
Open Access | Times Cited: 361
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks, Christopher B. Thorne, C. Brendan Clark, et al.
Journal of Psychopharmacology (2015) Vol. 29, Iss. 3, pp. 280-288
Closed Access | Times Cited: 339
Psychedelics as Medicines: An Emerging New Paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 209-219
Closed Access | Times Cited: 296
LSD‐induced entropic brain activity predicts subsequent personality change
Alexander V. Lebedev, Mendel Kaelen, Martin Lövdén, et al.
Human Brain Mapping (2016) Vol. 37, Iss. 9, pp. 3203-3213
Open Access | Times Cited: 287
Emotions and brain function are altered up to one month after a single high dose of psilocybin
Frederick S. Barrett, Manoj K. Doss, Nathan D. Sepeda, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 284
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Alan K. Davis, Frederick S. Barrett, Roland R. Griffiths
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 39-45
Open Access | Times Cited: 279
Psychiatry & the psychedelic drugs. Past, present & future
James Rucker, Jonathan Iliff, David Nutt
Neuropharmacology (2017) Vol. 142, pp. 200-218
Open Access | Times Cited: 276
Page 1 - Next Page

Scroll to top